Microbiotica
Microbiotica Raises £36M Series C for Oral Microbiome Medicines
Microbiotica announced £36M ($48M) in Series C financing on October 16, 2026. Microbiotica announced the first close of a £36 million ($48 million) Series C led by British Business Bank to advance MB310 into Phase 2 clinical development in ulcerative colitis.
Round details
The financing includes backing from British Business Bank, Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, Seventure Partners. The company did not publish a valuation with the announcement.
- Round: Series C
- Capital announced: £36M ($48M)
- Headquarters: Chesterford Research Park, near Cambridge, UK
How the company plans to use the capital
Microbiotica said proceeds will support the advancement of MB310 into Phase 2 clinical development in ulcerative colitis, following positive results from its Phase 1b COMPOSER-1 study. The company described the planned Phase 2 study as randomised, double-blind and placebo controlled.
Why this matters for GTM teams
All existing Series B investors participated in the financing, which was led by British Business Bank, according to Microbiotica.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Microbiotica Series C announcement.
Company Info
Investors (6)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


